Fisher & Paykel Healthcare updates 2027 profit guidance
- The company reported an estimated NZ$1.24 billion in half-year revenue based on current exchange rates.
- Executives updated the full-year net profit target to a range of NZ$525 million to NZ$565 million.
- The business stated that hospital hardware demand and internal operating efficiencies justified the revised financial outlook.
Fisher & Paykel Healthcare (ASX:FPH) increased its 2027 profit guidance to $525–565 million, citing strong hardware demand.
The updated forecast replaces earlier May expectations, which projected a full-year net profit range of NZ$500–NZ$550 million.
The full year guidance previously provided in May was for operating revenue to be in the range of approximately NZ$2.45 billion to NZ$2.57 billion.
The company reported an estimated NZ$1.24 billion in half-year revenue based on current exchange rates.
"We have had a strong start to our first half, particularly in our hospital product group, as a result of continued strong demand for our latest range of hardware devices and ongoing change in clinical practice driving consumable sales," said Fisher & Paykel Healthcare CEO Lewis Gradon.
Executives stated the revised net profit includes NZ$23 million in US tariff refunds.
Anticipating sustained operational growth following the announcement, the Fisher & Paykel Healthcare share price was up at $35.74.
The company manufactures clinical respiratory technology, which executives stated supports clinicians in adapting new care delivery methods.
Management stated that continuous internal improvement activities are currently underway to increase gross margins across the business.
